Q4 2025 Corcept Therapeutics Inc Earnings Call Transcript
Key Points
- Corcept Therapeutics Inc (CORT) reported a revenue increase to $761 million in 2025, up from $675 million in the previous year.
- The company provided optimistic revenue guidance for 2026, projecting between $900 million to $1 billion.
- Corcept Therapeutics Inc (CORT) experienced a surge in demand for its Cushing's syndrome medications, with a 37% increase in tablets delivered and a 61% increase in new prescriptions.
- The company successfully transitioned to a new specialty pharmacy with greater capacity, which is expected to improve service and meet growing demand.
- Positive results from the Catalyst trial showed significant benefits in treating patients with resistant diabetes and hypercortisolism, indicating potential for future growth.
- Net income for 2025 decreased to $99.7 million from $141.2 million in the prior year.
- The Federal Circuit Court of Appeals ruled against Corcept Therapeutics Inc (CORT) in a lawsuit to stop Teva Pharmaceuticals from marketing a generic version of their drug.
- The FDA did not approve Relicorant as a treatment for Cushing's syndrome, despite meeting primary endpoints in trials.
- The transition to a new pharmacy vendor caused disruptions in business operations during November, December, and January.
- There is uncertainty regarding the FDA's concerns about Relicorant's safety, particularly related to liver enzyme elevation, which may require further studies or appeals.
Thank you for standing by and welcome to Cose of Therapeutics 4th quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session you will need to press 11 on your telephone. To remove yourself from the queue, you may press 11 again. I would now like to hand the call over to Ataba Makari, CFO. Please go ahead.
Hello, everyone. Good afternoon and thank you for joining us. Today, we issued a press release announcing our financial results for the full year and providing a corporate update. A copy is available at coup.com. Our complete financial results will be available when we file our Form 10k with the SEC. Today's call is being recorded. A replay will be available at the investors past events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
